HSPB3 and neoplasm: The upregulation of HSPB3 expression in CRC patients was associated with poor RFS and OS regardless of their tumor stage or grade; therefore, this study suggested that HSPB3 is an excellent prognostic marker for CRC, regardless of clinicopathological prognosticators [34].